ZA200402755B - Controlled release polymeric compositions of bone growth promoting compounds. - Google Patents
Controlled release polymeric compositions of bone growth promoting compounds. Download PDFInfo
- Publication number
- ZA200402755B ZA200402755B ZA200402755A ZA200402755A ZA200402755B ZA 200402755 B ZA200402755 B ZA 200402755B ZA 200402755 A ZA200402755 A ZA 200402755A ZA 200402755 A ZA200402755 A ZA 200402755A ZA 200402755 B ZA200402755 B ZA 200402755B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- compound
- polymer
- amino
- phenoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 140
- 239000000203 mixture Substances 0.000 title claims description 139
- 230000008468 bone growth Effects 0.000 title description 69
- 230000001737 promoting effect Effects 0.000 title description 68
- 238000013270 controlled release Methods 0.000 title description 14
- 229920000642 polymer Polymers 0.000 claims description 122
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 106
- 230000009969 flowable effect Effects 0.000 claims description 52
- 229920001577 copolymer Polymers 0.000 claims description 42
- 239000002904 solvent Substances 0.000 claims description 38
- 239000007943 implant Substances 0.000 claims description 37
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 31
- 229920001169 thermoplastic Polymers 0.000 claims description 31
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 26
- 159000000000 sodium salts Chemical class 0.000 claims description 25
- 239000010839 body fluid Substances 0.000 claims description 24
- 210000001124 body fluid Anatomy 0.000 claims description 24
- 238000011065 in-situ storage Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 19
- WOHRHWDYFNWPNG-UHFFFAOYSA-N evatanepag Chemical compound C1=CC(C(C)(C)C)=CC=C1CN(S(=O)(=O)C=1C=NC=CC=1)CC1=CC=CC(OCC(O)=O)=C1 WOHRHWDYFNWPNG-UHFFFAOYSA-N 0.000 claims description 17
- 239000003960 organic solvent Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 13
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- -1 3,5-dichloro-phenoxy Chemical group 0.000 claims description 7
- LMIHDKFZOCIOPZ-UHFFFAOYSA-N 7-[(4-butylphenyl)methyl-methylsulfonylamino]heptanoic acid Chemical compound CCCCC1=CC=C(CN(CCCCCCC(O)=O)S(C)(=O)=O)C=C1 LMIHDKFZOCIOPZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000009792 diffusion process Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 5
- DWLYPVVWVSFAEO-UHFFFAOYSA-N 7-[2-(3,5-dichlorophenoxy)ethyl-methylsulfonylamino]heptanoic acid Chemical compound OC(=O)CCCCCCN(S(=O)(=O)C)CCOC1=CC(Cl)=CC(Cl)=C1 DWLYPVVWVSFAEO-UHFFFAOYSA-N 0.000 claims description 5
- 229920000954 Polyglycolide Polymers 0.000 claims description 5
- 230000003628 erosive effect Effects 0.000 claims description 5
- 238000010952 in-situ formation Methods 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- 229920003177 water-insoluble biodegradable polymer Polymers 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 description 31
- 230000007547 defect Effects 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 210000000988 bone and bone Anatomy 0.000 description 24
- 208000010392 Bone Fractures Diseases 0.000 description 23
- 238000009472 formulation Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 241000282472 Canis lupus familiaris Species 0.000 description 20
- 229920001223 polyethylene glycol Polymers 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 239000000499 gel Substances 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 206010017076 Fracture Diseases 0.000 description 12
- 210000000689 upper leg Anatomy 0.000 description 12
- 230000035876 healing Effects 0.000 description 11
- 238000013268 sustained release Methods 0.000 description 10
- 239000012730 sustained-release form Substances 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000002449 bone cell Anatomy 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 206010061363 Skeletal injury Diseases 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002601 radiography Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 208000008924 Femoral Fractures Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000011734 sodium Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 210000000623 ulna Anatomy 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000003044 Closed Fractures Diseases 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- 229960001172 doxycycline hyclate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000000528 lesser trochanter Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000007409 radiographic assessment Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33725501P | 2001-11-30 | 2001-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200402755B true ZA200402755B (en) | 2005-04-08 |
Family
ID=23319774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200402755A ZA200402755B (en) | 2001-11-30 | 2004-04-08 | Controlled release polymeric compositions of bone growth promoting compounds. |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US20030104031A1 (hr) |
| EP (1) | EP1448166A1 (hr) |
| JP (1) | JP4903985B2 (hr) |
| KR (1) | KR100629380B1 (hr) |
| CN (1) | CN1599598A (hr) |
| AP (1) | AP1781A (hr) |
| AR (1) | AR037462A1 (hr) |
| AU (2) | AU2002347502A1 (hr) |
| BR (1) | BR0214610A (hr) |
| CA (1) | CA2468703C (hr) |
| DO (1) | DOP2002000534A (hr) |
| EA (1) | EA011350B1 (hr) |
| EC (1) | ECSP045124A (hr) |
| GE (1) | GEP20063951B (hr) |
| GT (1) | GT200200242A (hr) |
| HR (1) | HRP20040486A2 (hr) |
| HU (1) | HUP0402135A3 (hr) |
| IL (1) | IL161835A0 (hr) |
| IS (1) | IS7217A (hr) |
| MA (1) | MA27084A1 (hr) |
| MX (1) | MXPA04003723A (hr) |
| NO (1) | NO20042273L (hr) |
| NZ (1) | NZ533115A (hr) |
| OA (1) | OA12731A (hr) |
| PA (1) | PA8559001A1 (hr) |
| PE (1) | PE20030581A1 (hr) |
| PL (1) | PL370085A1 (hr) |
| SV (1) | SV2004001421A (hr) |
| TN (1) | TNSN04096A1 (hr) |
| TW (1) | TW200300695A (hr) |
| UA (1) | UA76792C2 (hr) |
| WO (1) | WO2003045351A1 (hr) |
| YU (1) | YU35004A (hr) |
| ZA (1) | ZA200402755B (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074425B2 (en) * | 2002-09-26 | 2006-07-11 | Bonewax, Llc | Hemostatic compositions and methods |
| WO2004071356A2 (en) * | 2003-02-10 | 2004-08-26 | Smith & Nephew, Inc. | Resorbable devices |
| GB0307011D0 (en) | 2003-03-27 | 2003-04-30 | Regentec Ltd | Porous matrix |
| JP2007507516A (ja) * | 2003-10-01 | 2007-03-29 | オプティマー・ファーマスーティカルズ・インコーポレイテッド | アミノ糖投与による哺乳動物の障害の治療及びアミノ糖の使用 |
| GB0329654D0 (en) | 2003-12-23 | 2004-01-28 | Smith & Nephew | Tunable segmented polyacetal |
| US8123787B2 (en) | 2004-10-28 | 2012-02-28 | Ogilvie James W | Method of treating scoliosis using a biological implant |
| US8641738B1 (en) | 2004-10-28 | 2014-02-04 | James W. Ogilvie | Method of treating scoliosis using a biological implant |
| AU2006281248A1 (en) * | 2005-08-18 | 2007-02-22 | Smith & Nephew, Plc | High strength devices and composites |
| CN100443065C (zh) * | 2006-01-26 | 2008-12-17 | 上海交通大学 | 用于颌面骨缺损修复的复合体系植入体单元 |
| JP2010511751A (ja) | 2006-11-30 | 2010-04-15 | スミス アンド ネフュー インコーポレーテッド | 繊維強化複合材料 |
| EP2142353A1 (en) | 2007-04-18 | 2010-01-13 | Smith & Nephew PLC | Expansion moulding of shape memory polymers |
| WO2008131197A1 (en) | 2007-04-19 | 2008-10-30 | Smith & Nephew, Inc. | Multi-modal shape memory polymers |
| WO2008130954A2 (en) | 2007-04-19 | 2008-10-30 | Smith & Nephew, Inc. | Graft fixation |
| US8062739B2 (en) * | 2007-08-31 | 2011-11-22 | Zimmer, Inc. | Hydrogels with gradient |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| AU2009281223B2 (en) | 2008-08-12 | 2014-01-09 | Novartis Ag | Pharmaceutical compositions |
| EP2172189A1 (en) * | 2008-10-01 | 2010-04-07 | Novartis AG | Pharmaceutical Compositions |
| EP2346421A1 (en) * | 2008-10-15 | 2011-07-27 | Bioshape Solutions Inc. | Device and method for delivery of therapeutic agents via internal implants |
| US9642658B2 (en) | 2008-10-15 | 2017-05-09 | Orthoclip Llc | Device and method for delivery of therapeutic agents via internal implants |
| CN102470184B (zh) | 2009-08-06 | 2017-05-31 | 皇家飞利浦电子股份有限公司 | 采用放射性种子的肿瘤治疗 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| CN104189954B (zh) * | 2014-09-19 | 2017-03-29 | 中国科学院长春应用化学研究所 | 一种原位固化组织工程支架及其制备方法 |
| RU2571548C1 (ru) * | 2014-12-17 | 2015-12-20 | Федеральное государственное бюджетное учреждение науки Институт органической и физической химии им. А.Е. Арбузова Казанского научного центра Российской академии наук | Ветеринарное имплантируемое средство пролонгированного действия (варианты) |
| SG11201804037XA (en) | 2015-11-16 | 2018-06-28 | Evonik Roehm Gmbh | Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) |
| CN109498852B (zh) * | 2018-12-29 | 2022-06-24 | 广州噢斯荣医药技术有限公司 | 治疗骨科疾病的生物降解材料及其应用 |
| US20220409642A1 (en) | 2019-11-04 | 2022-12-29 | Astrazeneca Ab | Combination therapy for treating cancer |
| KR20230150790A (ko) | 2020-12-29 | 2023-10-31 | 시노 메디칼 사이언시즈 테크놀로지, 인코포레이티드 | 약물 용출 스텐트 |
| WO2024089418A1 (en) | 2022-10-24 | 2024-05-02 | Cancer Research Technology Limited | Tumour sensitisation to checkpoint inhibitors with redox status modifier |
| WO2024089417A1 (en) | 2022-10-24 | 2024-05-02 | Memorial Sloan-Kettering Cancer Center | Tumour stratification for responsiveness to an immune checkpoint inhibitor |
| WO2024150017A1 (en) | 2023-01-13 | 2024-07-18 | Akrivia Biomedics Limited | Method of profiling diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE241394T1 (de) * | 1994-04-08 | 2003-06-15 | Atrix Lab Inc | Beigeordnetes polymersystem zur verwendung mit einer medizinischen vorrichtung |
| AU4652596A (en) | 1995-01-09 | 1996-07-31 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
| UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| ATE318580T1 (de) * | 1996-12-20 | 2006-03-15 | Alza Corp | Gelzusammensetzungen und verfahren |
| UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| US7128927B1 (en) * | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
-
2002
- 2002-11-20 HU HU0402135A patent/HUP0402135A3/hu unknown
- 2002-11-20 GE GE5596A patent/GEP20063951B/en unknown
- 2002-11-20 AU AU2002347502A patent/AU2002347502A1/en not_active Abandoned
- 2002-11-20 NZ NZ533115A patent/NZ533115A/en unknown
- 2002-11-20 EP EP02783436A patent/EP1448166A1/en not_active Withdrawn
- 2002-11-20 WO PCT/IB2002/004965 patent/WO2003045351A1/en active IP Right Grant
- 2002-11-20 CA CA002468703A patent/CA2468703C/en not_active Expired - Fee Related
- 2002-11-20 OA OA1200400150A patent/OA12731A/en unknown
- 2002-11-20 IL IL16183502A patent/IL161835A0/xx unknown
- 2002-11-20 PL PL02370085A patent/PL370085A1/xx not_active Application Discontinuation
- 2002-11-20 AP APAP/P/2004/003037A patent/AP1781A/en active
- 2002-11-20 YU YU35004A patent/YU35004A/sh unknown
- 2002-11-20 EA EA200400608A patent/EA011350B1/ru not_active IP Right Cessation
- 2002-11-20 CN CNA028239687A patent/CN1599598A/zh active Pending
- 2002-11-20 MX MXPA04003723A patent/MXPA04003723A/es active IP Right Grant
- 2002-11-20 BR BR0214610-0A patent/BR0214610A/pt not_active IP Right Cessation
- 2002-11-20 UA UA20040504054A patent/UA76792C2/uk unknown
- 2002-11-20 JP JP2003546854A patent/JP4903985B2/ja not_active Expired - Fee Related
- 2002-11-20 KR KR1020047008243A patent/KR100629380B1/ko not_active IP Right Cessation
- 2002-11-25 US US10/303,590 patent/US20030104031A1/en not_active Abandoned
- 2002-11-27 GT GT200200242A patent/GT200200242A/es unknown
- 2002-11-27 PE PE2002001144A patent/PE20030581A1/es not_active Application Discontinuation
- 2002-11-28 DO DO2002000534A patent/DOP2002000534A/es unknown
- 2002-11-28 PA PA20028559001A patent/PA8559001A1/es unknown
- 2002-11-28 AR ARP020104597A patent/AR037462A1/es unknown
- 2002-11-29 TW TW091134882A patent/TW200300695A/zh unknown
- 2002-11-29 SV SV2002001421A patent/SV2004001421A/es not_active Application Discontinuation
-
2004
- 2004-04-07 IS IS7217A patent/IS7217A/is unknown
- 2004-04-08 ZA ZA200402755A patent/ZA200402755B/en unknown
- 2004-05-20 MA MA27688A patent/MA27084A1/fr unknown
- 2004-05-28 EC EC2004005124A patent/ECSP045124A/es unknown
- 2004-05-28 TN TNP2004000096A patent/TNSN04096A1/fr unknown
- 2004-05-31 HR HR20040486A patent/HRP20040486A2/hr not_active Application Discontinuation
- 2004-06-01 NO NO20042273A patent/NO20042273L/no not_active Application Discontinuation
-
2008
- 2008-10-24 US US12/257,803 patent/US8017144B2/en not_active Expired - Fee Related
-
2009
- 2009-01-13 AU AU2009200125A patent/AU2009200125B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8017144B2 (en) | Controlled release polymeric compositions of bone growth promoting compounds | |
| EP0608313B1 (en) | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins | |
| JP6087886B2 (ja) | 改良された効力を備えた、ロイプロリドのポリマー送達処方物 | |
| JP5878477B2 (ja) | 骨の治癒を加速するためのバナジウム化合物の使用 | |
| MX2012013937A (es) | Composicion antipsicotica inyectable de liberacion controlada. | |
| AU2005315823B2 (en) | In-situ forming implant for animals | |
| RU2360663C1 (ru) | Гель для регенерации костной ткани | |
| US20220152270A1 (en) | Long lasting biodegradable polymer based in-situ forming implant for treatment of bone injuries | |
| RU2155049C1 (ru) | Композиция для костной пластики | |
| US20180318344A1 (en) | Zinc or manganese compounds as therapeutic adjuncts for cartilage regeneration and repair | |
| Kangur et al. | The use of methylmethacrylate in the fixation of mandibular fractures in dogs: Experimental results | |
| US20090292013A1 (en) | In-Situ Forming Implant for Animals |